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ABSTRACT
Gene therapy by engineering patient’s own blood
cells to confer HIV resistance can potentially lead
to a functional cure for AIDS. Toward this goal, we
have previously developed an anti-HIV lentivirus vec-
tor that deploys a combination of shRNA, ribozyme
and RNA decoy. To further improve this therapeu-
tic vector against viral escape, we sought an addi-
tional reagent to target HIV integrase. Here, we re-
port the development of a new strategy for selec-
tion and expression of aptamer for gene therapy. We
developed a SELEX protocol (multi-tag SELEX) for
selecting RNA aptamers against proteins with low
solubility or stability, such as integrase. More im-
portantly, we expressed these aptamers in vivo by
incorporating them in the terminal loop of shRNAs.
This novel strategy allowed efficient expression of
the shRNA–aptamer fusions that targeted RNAs and
proteins simultaneously. Expressed shRNA–aptamer
fusions targeting HIV integrase or reverse transcrip-
tase inhibited HIV replication in cell cultures. Viral in-
hibition was further enhanced by combining an anti-
integrase aptamer with an anti-HIV Tat-Rev shRNA.
This construct exhibited efficacy comparable to that
of integrase inhibitor Raltegravir. Our strategy for the
selection and expression of RNA aptamers can po-
tentially extend to other gene therapy applications.
INTRODUCTION
Human immunodeficency virus (HIV) that causes acquired
immunodeficiency syndrome (AIDS) is rapidly evolving.
The current standard of treatment of combinatorial anti-
retroviral therapy (ART) is very effective in controlling vi-
ral loads, however, ART is not curative. Patients have to en-
dure high costs and potential side effects associated with
the lifelong treatment. Gene therapy presents an attractive
alternative treatment. By engineering patients’ own T cells
or hematopoietic stem cells to confer HIV resistance, gene
therapy can potentially lead to a functional cure for AIDS
(1–3).
One of themajor challenges in targetingHIV is its rapidly
evolving genome that leads to drug resistance. Therefore,
combinatorial strategies to simultaneously target different
steps of the HIV life cycle are essential for successful gene
therapy. Early attempts of combinatorial gene therapy that
included RNA-based as well as protein-based strategies
have proven to be very effective in cell culture and animal
models (4–7). With intrinsic low immunogenic properties,
multiplexing ability and small size, RNA-based reagents
such as shRNAs, ribozymes and RNA decoys are excellent
building blocks for combinatorial anti-HIV vectors. Most
of these RNA-based therapeutics target the HIV genes or
genome by base-pairing that can be attenuated by pointmu-
tation(s) in the target site. Additional RNA-based reagents
that are independent of base-pairing will further enhance
our combinatorial strategy for anti-HIV gene therapy.
One such class of reagents is RNA aptamers, which are
short single stranded RNAs that fold into stable three-
dimensional shapes.With close to unlimited potential struc-
tural conformations, aptamers are very attractive molecules
for structure based targeting. Aptamers with high affinity
and specificity to target proteins can be selected from com-
plex libraries using SELEX (Selective Enrichment of Lig-
ands by Exponential Enrichment) (8,9). Recently, aptamers
with high binding affinity against HIV RT, gp120, Gag and
Protease have been isolated (10–15). Currently, most thera-
peutic aptamers are administered exogenously to target cell
surface proteins either as neutralizing reagents or as vehicles
to carry therapeutic agents (14,16,17). RNA aptamers tran-
scribed from Pol III promoter such as U6 have precise start
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and termination sites allowing precise prediction of length
and structure of the expressed aptamers. However, Pol III
driven transcripts do not contain an intrinsic nuclear export
signal and predominantly reside in the nucleus (18–21), ex-
cluding their use against the proteins that function in the
cytoplasm.While aptamers transcribed fromPol II promot-
ers can be exported to the cytoplasm, the additional 5′ and
3′ sequences, the 5′ cap and the polyA tail as well as their
binding proteins, may alter the structure and interfere with
the aptamers’ function. Expression of functional aptamers
in cells remains a major hurdle for long-term gene therapy.
Here, we report a novel strategy for the selection and
stable expression of aptamer therapeutics. We developed a
multi-tag SELEX method for selecting aptamers that tar-
get proteins with low solubility and/or stability, such as
the HIV integrase. We took advantage of the mechanism of
Exportin-5 mediated export of pre-miRNAs and designed
shRNA–aptamer fusions by incorporating the aptamers as
the terminal loop of shRNAs.We demonstrated that the ex-
pressed shRNA–aptamer fusions could exert prolonged in-
hibition of HIV replication.
MATERIALS AND METHODS
Vectors construction
To construct a maltose binding protein-integrase fusion
(MBP-IN) expression vector (pJR166), an NdeI and
BamHI fragment containing the IN coding region of pNL4-
3 strain was released from pEt-15b-IN (22,23) and cloned
into pMAL-c5X (New England Biolabs, Ispwich, MA,
USA). To generate a FLAG tagged IN mammalian expres-
sion vector, a human codon optimized integrase coding se-
quence was synthesized according to the amino acid se-
quence of pEt-15b-IN and cloned into a pCDNA3 based
vector (Thermofisher, Grand Island, NY, USA) that con-
tains an N-terminal FLAG tag (pJR188). For expression
of shRNAs and aptamers in mammalian cells, a plasmid
(pJR255) was constructed that contained aU6 promoter for
driving expression of the shRNAs, aptamers, or shRNA–
aptamer fusions. It also contained an mCherry visible
marker driven by CMV promoter. Two BbsI sites were in-
serted directly downstream of the U6 promoter to generate
GTGG and TTTT overhangs upon cleavage. pJR255 was
used to drive expression of shRNA and aptamers in HEK
293 cells and Ghost(3) CXCR4+/CCR5+ cells. Because
CMV promoter-driven mCherry showed very weak signal
in CEM cells, a similar plasmid (pJR288) was constructed
that replaced the CMV promoter with the Ef1 promoter.
For construction of various U6 driven shRNAs, aptamers
or shRNA–aptamer fusions, 1 nmol each of oligonucleotide
pair containing CACC and AAAA overhangs (Supplemen-
tary Table S1) was mixed in 1X T4 Ligase buffer (NEB),
heated to 95◦C for 3 min, slowly cooled to room tempera-
ture, and then ligated to the BbsI cut of either pJR255 or
pJR288.
Production and purification of integrase fusion proteins
HIS tag HIV-1 integrase (HIS-IN) expression vector was
a gift from Dr. Robert Craigie (NIDDK, NIH) (23). Es-
cherichia coli strain C3016 (NEB, Ipswich, MA, USA) was
transformed with the HIS-IN plasmid. A single positive
colony was picked to inoculate 250 ml of SOBmedium con-
taining 100 mg/ml of ampicillin. The culture was grown
overnight in a 37◦C shaker (200 rpm). Induction was per-
formed by adding 250 ml of fresh SOB containing 2 mM
IPTG for another 3 hours at 22◦C. HIS-IN was purified
from bacterial cells with Ni-NTA agarose (Qiagen, Valen-
cia, CA, USA.) using the manufacturer’s protocol for puri-
fying protein in native conformation. To increase the pu-
rity of the eluted protein, beads were washed first with
buffer containing 300 mMNaCl and 50 mM imidazole fol-
lowed by a second wash with buffer containing 500 mM of
NaCl and 30 mM imidazole. Eluted HIS-IN was dialyzed
overnight at 4◦Cwith two changes of 500ml PBS. Induction
and lysis of maltose binding protein (MBP)-IN followed a
similar protocol. MBP-IN was purified with pMAL pro-
tein fusion purification system (NEB, Ipswich, MA, USA).
Eluted fusion protein was dialyzed against two changes of
500 ml of PBS at 4◦C overnight. Purity and concentration
of HIS-IN andMBP-IN fusion proteins were quantified by
serial dilution and PAGE analysis using a BSA standard.
FLAG-IN and associated protein complexes were pu-
rified from pJR188-transfected HEK293 cells, 48 h post-
transfection, using the M2 anti-FLAG affinity gel accord-
ing to the manufacturer’s protocol (Sigma-Aldrich, St.
Louis, MO, USA).
Aptamer selection, identification and structure prediction
Aptamer selections basically followed Zhou et al. (10) with
the following modifications. Two bacterially expressed fu-
sions HIS-IN and MBP-IN were used alternatively in each
cycle of selection and a mammalian cell expressed FLAG-
IN was used in an additional cycle of enrichment. To in-
crease the complexity of the library, primer extension with
T4 polymerase instead of PCR was used to generate a dou-
ble stranded template DNA from an oligonucleotide library
that contained a 5′ T7 promoter sequence, a 30-nucleotide
variable middle region (n), and a 3′ constant region (Sup-
plementary Table S1). In addition, RT-PCR reactions were
limited to 10 cycles of amplification. The RNA library was
generated by Megashortscript T7 transcription kit (Ther-
mofisher Scientific, Waltham, MA, USA), using the gel pu-
rified RT-PCR product as a template.
In each cycle of selection, RNA pools were folded in 200
l of binding buffer (PBS pH 7.4 plus 1 mM CaCl2, 2.7
mM KCl, 2 mM MgCl2) by heating to 95◦C for 3 min fol-
lowed by slow cool to 37◦C. The folded RNA pools were
then pre-cleared by incubating with HAWP filter (0.45 m
pore size, 13 mm diameter, EMDMillipore, Concord, MA,
USA) for 30 min. The tagged IN proteins were then incu-
bated with the pre-cleared RNA pool in phosphate buffer
(pH 7.4) using progressively increased NaCl concentrations
in SELEX cycles (50 mM in cycle 1–2, 100 mM in cycle 3–
4, 147 mM in cycle 5 and up) and incubated for an addi-
tional 15 min at 37◦C. In the first selection cycle, 1.5 nmol
of RNA and 0.24 nmol of protein (RNA to protein ratio
of 6.5:1) were used for binding reaction. As selection cycle
progressed, protein concentration was gradually decreased
to 0.12 nmol. Starting from cycle 3, an increasing amount
of tRNA (20 g in cycle 3–4, 40 g in cycle 5–6, 80 g in
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cycle 7 and up) was added as nonspecific competitor. The
RNA–protein complexes were isolated by passing the reac-
tion through a HAWP filter, followed by 1 ml washes with
binding buffer.Membrane boundRNAs were eluted by 200
l of elution buffer (7 M urea and 5 mM EDTA) at 95◦C
for 5 min, followed by phenol/chloroform extraction. An
additional round of selection was carried out with FLAG-
IN complexes immuno-precipitated from 1 mg of HEK293
cell lysate with 180 l of M2 anti-FLAG affinity gel beads.
The complex was then used to bind to 60 g of RNA with
180 g of tRNA as nonspecific competitor.
RT-PCRproducts of the final three cycles of selection and
the sample binding to FLAG-IN complexes were subjected
to high throughput sequencing (Illumina). Sequence anal-
ysis was performed as described (24). Secondary structure
predictions were carried out by Mfold web server (25).
Gel mobility shift, binding assay and northern analysis
A filter binding assay was carried out to monitor library
enrichment. 5 g of aptamer RNAs from each cycle were
first treated with Antarctic phosphatase (NEB), followed by
phenol extraction and ethanol precipitation. Dephosphory-
lated RNA pellets were resuspended in PBS and their con-
centrations were determined by nanodrop spectrometer. 10
pmol of aptamer RNA was then end labeled with 32P ATP
with T4 polynucleotide kinase (NEB), adjusted to 200 nM
with PBS then purified by G25 column (GE Life Sciences).
Half of the 32P-labeled aptamer RNAwas folded by heating
(95◦C for 3 min) and slow cooling (37◦C on heat block). 1
pmol of folded RNA was incubated with 10 pmol of MBP-
IN and 10 pmol of tRNA at 37◦C for 20 min. The reac-
tions were passed through nitrocellulose filters (0.45 m
pore size, 13 mm diameter, EMDMillipore, Concord, MA,
USA) which were then washed with 1 ml PBS. Radioactiv-
ity of the filters containing aptamer–protein complexes was
determined by scintillation counter using 1 pmol of labeled
RNA as standard.
The gel mobility shift assay was carried out as de-
scribed (10). RNA aptamers were transcribed from an-
nealed oligonucleotide pairs (Supplementary Table S1) con-
taining T7 promoter sequences using Megashortscript T7
transcription kit (Thermofisher Scientific, Waltham, MA,
USA). 32P labeled and folded aptamers (final concentra-
tion of 2 nM) were incubated with HIS-IN protein (final
concentration of 0, 20, 40, 80, 160 and 320 nM) at 37◦C
for 30 min. The complexes were then separated by 5% na-
tive polyacrylamide gel. Autoradiographs were acquired via
Typhoon phosphorimaging system (GE Healtcare Life Sci-
ence, Pittsburgh PA, USA). Digital images were imported
and analyzed by ImageJ software (http://imagej.nih.gov/ij/
index.html). 50 percent binding values were determined by
the Prism 6 software (GraphPad Software Inc) using non-
linear curve regression.
Northern analysis of total and fractionated RNAs was
carried out as described (26) using probes listed in primer
list (Supplementary Table S1). Quantification of relative
band intensity was measured and calculated using ImageJ
software.
Cell culture and generation of stable cell lines
Ghost(3) CXCR4+CCR5+ cells (27), HIV pNL4-3 (22)
and Ba-L (28) strains were obtained from NIH AIDS
Reagent Program (see acknowledgement). Ghost3 cells and
HEK293 cells (ATCC CRL-1573) were grown on DMEM
supplemented with 10% FBS and 1 mM glutamine. CCRF-
CEM (ATCC CRM-CCL-119) cells were grown in RPMI
supplemented with 10% FBS and 1 mM glutamine.
HEK293 and Ghost3 were transfected with Lipofec-
tamine 2000 according to the manufacturer’s protocol
(ThermoFisher, Waltham, MA, USA). To generate stable
HEK293 cell lines, 2 million cells were transfected with
pJR255-based plasmids that express aptamers alone, shLuc
or shLuc-aptamer fusions. Transfected cells were selected
with G418 (Gold Biotechnology, St. Louis, MO, USA) for
10–14 days, followed by Fluorescent Activated Cell Sort-
ing (FACS) to isolated mCherry positive cells. Typically, the
brightest 10–30% of cells were collected. Second FACS was
performed 7–10 days after the first sort to isolate stable cell
populations. Cells isolated from second sort (typically 40–
60%of cells) had a very stablemCherry signal andwere used
for lentivirus or HIV challenge experiments. Ghost3 cells
were already G418 resistant, therefore, no selection step
was performed. 0.5 M cells were transfected with pJR255
based plasmids that express shLuc, aptamer alone or shLuc-
aptamer fusions. Transfected cells were sorted 7 days after
transfection. Compared to HEK293 cells, the percentage of
mCherry positive cells was much lower because no drug se-
lection was applied. Typically, the brightest 5–10% of cells
were collected. A second sort was performed 14 days later.
If a decrease in mCherry signal was observed, a third sort
was performed.
To generate stable CCRF-CEM cell lines, 2 million cells
were transfected with pJR288-based plasmids, that ex-
press shLuc, shLuc-S1R1, shLuc-S3R1 and shLuc–S3R3,
by electroporation using the Nucleofactor kit according to
the manufacturer’s protocol (Lonza, Basel, Switzerland).
G418 selection and FACS were performed similar to that
of HEK293 cells.
HIV challenge assay
For lentivirus challenge, 5 × 104 HEK293 cells stably ex-
pressing aptamer alone, shRNA alone or shRNA–aptamer
fusion were transduced with HIV7-GFP (29) lentiviral par-
ticles at a MOI of 0.3 in 500 l medium. Cells were har-
vested 10 days post-transduction and analyzed by FACS.
For HIV challenge, 5 × 104 Ghost3 cells stably express-
ing shRNA alone or shRNA–aptamer fusions were infected
with HIV-1 Ba-L strain at MOI of 0.02 in 500 l medium.
Viral concentration in culture was determined by p24 as-
say using Alliance HIV-1 p24 ELISA kit (PerkinElmer,
Waltham, MA, USA).
For long term HIV challenge, 1 × 105 CCRF-CEM cells
stably expressing shRNA or shRNA–aptamer fusions were
infected with HIV-1 NL4-3 viruses atMOI of 0.02 in 500 l
medium. OnDay 3, cells were collected by centrifugation at
200 × g for 3 min and resuspended in 1ml fresh medium.
From week 1 to week 6 post-infection, 500 l of cell cul-
tures were collected for analysis and the continuing cultures
was replenished with 500 l fresh medium. In addition, to
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maintain an unsaturated cell density, 50% of cells was also
replaced with fresh medium at mid-week time points.
Luciferase assay
A HEK293 cell clone stably expressing firefly luciferase
was transfected with the plasmids expressing the shLuc
or the shLuc-aptamer fusions. Transfected cells were har-
vested two or three days post-transfection and their firefly
luciferase activities were determined by the Luciferase As-
say System (Promega, Madison, WI, USA).
RESULTS
Multi-tag SELEX
Our previous combinatorial anti-HIV vectors target multi-
ple steps of the HIV life cycle, including entrance, transcrip-
tion and replication (4,7,30). In this work, we sought to en-
hance our existing vector by including an expressed aptamer
that targets the HIV integrase. We used SELEX to isolate
RNA aptamers that bind to HIV integrase (IN). A bacte-
rially expressed HIS-tag mutant integrase (F185K/C280S)
that retains DNA integration activity but has much im-
proved solubility (23) was used for aptamer library enrich-
ment. Since we intended for the aptamers to be expressed
in T cells for anti-HIV gene therapy, salt concentrations of
less than 147 mM of sodium chloride were used for the en-
richment process. At low salt concentrations, the integrase
protein became poorly soluble and very unstable especially
when the tag was removed from the expressed fusion (Sup-
plementary Figure S1A and 1B and data not shown). There-
fore, the HIS-tag fusion protein was used for enrichment.
To minimize the enrichment of aptamers that bind to
HIS-tag rather than integrase, we employed two additional
tagged integrase fusions for aptamer selections. First, amal-
tose binding protein-tagged IN (MBP-IN) was expressed in
E. coli. Second, a FLAG-tagged IN (FLAG-IN) was ex-
pressed in human cells in a physiologically relevant envi-
ronment. Integrase interacts with a number of cellular pro-
teins (31–34). FLAG-IN that complexed with cellular pro-
teins presents a more native conformation that should facil-
itate the isolation of functional aptamers. Consistent with
previous reports, we observed very low expression of wild-
type integrase in mammalian cells (35). By codon optimiza-
tion, we were able to increase the yield of the protein by
more than ten-fold (Figure 1A). Since over-expression of
the active integrase could be toxic to cells, we also gener-
ated an inactive mutant D64V. However, we obtained sim-
ilar yields for both active and inactive forms from tran-
siently transfected cells (Figure 1A) hence we used the tran-
siently expressed active form for enrichment. A high pro-
portion (74%) of active FLAG-IN could be purified from
transfected HEK 293 cells (Figure 1B). However, the yield
was still too low to allow the use of purified complexes in
the early selection cycles that typically requires 10–20 g
of purified protein (Figure 1C). Therefore, bacterially ex-
pressed HIS-IN and MBP-IN (Supplementary Figure S1A
and B) were used alternately in the early selection cycles
while FLAG-IN complexes purified from human cells were
reserved for the final round of selection (Figure 1D). We
termed this strategy multi-tag SELEX.
Isolation of integrase binding aptamers
Enrichment of the library was monitored by an increase in
the percentage of binding toMBP-IN (Figure 1E). Samples
from cycles just reaching the plateau (typically cycle 11–
13) were subjected to an additional cycle of enrichment us-
ing the cellular complexes that co-immunoprecipitated with
FLAG-IN (Figure 1E). Samples of the final four cycles of
selections were subjected to high throughput sequencing (Il-
lumina). Four independent selections were performed (S1-
S4). Selection 2 did not yield any candidate aptamers that
were substantially enriched and was therefore rejected.
The most abundant aptamer isolated from the first se-
lection was designated as S1R1 (Selection 1, aptameR 1).
The sequence of S1R1 is identical to that of S3R2 and
S4R1. This aptamer is the most abundant, representing
8.1%, 26.6% and 35.7% of total reads in the three inde-
pendent selections S1, S3 and S4, respectively (Figure 2A
and B). In addition, aptamers S3R5 and S4R4 differed from
S1R1 by only one base and shared the same predicted sec-
ondary structure (Figures 2B and 3A). Moreover, aptamers
S1R2, S1R3, S1R4, S1R5 and S4R3 also shared similarly
predicted secondary structures as S1R1, having two stem-
loops separated by 4–10 single-stranded spacer nucleotides
(Figure 3B–E and K). Overall, aptamers with the predicted
two stem–loop structure represented the majority of ap-
tamers isolated, suggesting that aptamers with these struc-
tures might have high affinity to an exposed domain of in-
tegrase.
Functional assay for integrase binding aptamers
We intended to express the aptamers in T cells or
hematopoietic stem cells (HSC) for combinatorial gene
therapy. Therefore, we sought a direct functional assay to
test the inhibitory effect of the aptamer candidates. To this
end, we constructed plasmids (pJR255) consisting of (i) a
U6 promoter for driving the expression of the aptamers, (ii)
a G418-resistant cassette for selection and (iii) an mCherry
marker for cell purification and functional analysis (Sup-
plementary Figure S2). RNAs expressed from U6 (pol III)
promoter lack nucleus export signals and stay in the nucleus
(18–21). Integrase functions primarily in the nucleus. These
nuclear aptamers may be effective against its functions. We
first tested the aptamers with a distinct secondary structure,
namely S1R1, S3R1 and S3R3 for resistance to infection
of the self-inactivating (Sin) lentiviral vector (HIV-7-GFP)
(29). Stable HEK293 lines were established by transfecting
an empty plasmid backbone (negative control) or plasmids
expressing S1R1, S3R1 or S3R3, selecting for G418 resis-
tance and sorting for mCherry positive signals. Each pop-
ulation of cells was than transduced with lentiviral parti-
cles at an MOI of 0.3. The transduced cells were analyzed
by FACS 10 days after transduction to minimize the effects
of GFP signals from nonintegrated viral DNA. If an ap-
tamer exerts any inhibition of HIV integrase, the percent-
age of GFP andmCherry double-positive cells should be re-
duced compared to the control. By this measure, FACS data
showed that all three aptamers expressed directly from the
U6 promoter lacked any inhibition of the lentivirus infec-
tion, suggesting that integrase aptamers expressed directly
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Figure 1. Multiple tagged integrases for SELEX. (A) Codon optimization increased the yield of an active and an inactive FLAG-IN.Western blot showing
expression levels of FLAG-tagged original (wt), codon optimized active (D64) and codon-optimized inactive (V64) integrase from transiently transfected
HEK293 cells. Note that yield of codon-optimized FLAG-IN was still substantially lower than FLAG-mCherry positive control. (B) FLAG-IN (D64)
transiently expressed in HEK293 cells was purified by anti-FLAG M2 affinity gel (Sigma). Approximately 74% (compare lane 2 to lane 1) of FLAG-IN
expressed from HEK293 cells was purified. Fraction 1 to 5 represent purified FLAG-IN protein. (C) 10% of FLAG-IN purified from two 150 cm plates of
HEK 293 cells was not detectable by Coomassie staining. 0.5 g of purified HIS-IN and MBP-IN was added for comparison. (D) Schematic of multi-tag
SELEX strategy. (E) Typical change of aptamers binding during enrichment cycles monitored by the filter binding assay. Odd number cycles were enriched
by MBP-IN while even number cycles were enriched by His-IN. ‘*’ marks the sample used for one additional enrichment cycle with HEK293 expressed
FLAG-IN. High percentage binding at first two cycles probably represents high nonspecific binding to HIS andMBP tags. Alternate high and low binding
at later cycles probably represent populations showing higher binding affinity to MBP-IN than HIS-IN.
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BA
Figure 2. Similar aptamers were isolated in three independent selections. (A) Change of abundance of aptamers during the last four cycles of enrichment.
In most cases, further enrichment of aptamers was achieved by FLAG-IN. One aptamer (S1R1, S3R2 and S4R1 with identical sequence) dominated in all
three selections. S3 and S4 used a steeper slope of increasing stringency in selection cycles so plateau was reached at cycle 11, two cycles earlier than S1.
(B) Alignment of the most abundant 15 aptamers. Only sequences of the variable region of the aptamers are shown. Aptamers with identical sequences
were highlighted (red or blue) and the single base difference between S1R1 and S3R5 (red T and blue G) is shown.
from U6 promoter might not be effective against lentivirus
infection (Supplementary Figure S3A and 3B).
Aptamers incorporated into shRNA loops behave like canon-
ical shRNAs
Pre-miRNAs are exported to the cytoplasm mainly by
Exportin-5 that recognizes the 3′ two base overhangs of
the stem-loop structures (36,37). Some pre-miRNAs con-
tain large loops; nonetheless, these pre-miRNAs are still ef-
ficiently exported to the cytoplasm, cleaved by Dicer and
loaded into RNA Induced Silencing Complex (RISC) to
mediate silencing of target mRNAs (38,39). We took ad-
vantage of these properties to design a chimeric RNA thera-
peutic that incorporated the aptamer into the terminal loop
of an shRNA. This shRNA–aptamer fusion may be ex-
ported to the cytoplasm and processed by Dicer to release
the siRNA. In principle, either the released aptamer or the
unprocessed fusion could contribute to HIV inhibition.
First, we used a luciferase assay to test if the shRNA–
aptamer fusion could behave like a canonical shRNA that
is exported into the cytoplasm and processed by Dicer. A
HEK293 clone that stably expressed a firefly luciferase gene
was transfected with plasmids containing (i) only the U6
promoter, (ii) U6 driving a nonspecific shRNA (shNS), (iii)
U6 driving an shRNA targeting luciferase with an artificial
10-base loop (shLuc) (40) and (iv) shLuc with the aptamer
S1R1 as the loop (shLuc-S1R1) (Figure 4A). The shLuc-
S1R1 showed substantial knockdown of luciferase activ-
ity, albeit slightly weaker than the shLuc with 10-base loop
(Figure 4B). Similar results were observed with the shLuc
incorporated with three other aptamers S3R1, S3R3 and
S3R6 (Figure 4C). These results indicated that the shLuc–
aptamer fusions behaved like a canonical shRNA that could
be processed by Dicer to release the siLuc RNA, resulting
in knockdown of the luciferase target.
To further assess the distribution and processing of the
shLuc-aptamer fusion, we performed Northern blot analy-
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Figure 3. Predicted secondary structures of the 15 most abundant aptamers. Structure in panel (A) is shared with the most number of aptamers. S1R1 and
S3R5 differed only by a single base at (position 19) the loop of the first stem-loop structure.
ses on fractionated samples. When detecting the luciferase
guide strand, both shLuc and shLuc-S1R1 showed similar
steady state levels (Figure 4D, top panel). Moreover, both
shLuc and shLuc-S1R1 showed similar distributions be-
tween the nucleus (nu) and the cytoplasm (cy), indicating
that the large S1R1 loop neither destabilized the shRNA–
aptamer fusion nor hindered its nuclear export. Consistent
with the observed 20% weaker knockdown of luciferase ac-
tivity, 25% less processed siRNA was detected from shLuc-
S1R1 than from shLuc (Figure 4D top panel box), indi-
cating that the large S1R1 loop moderately inhibited Dicer
processing.
To further determine the fate of the aptamer S1R1 re-
leased from the shLuc-S1R1 fusion, we probed the same
blot with an S1R1 probe. When detected by the S1R1
probe, the shLuc-S1R1 fusion was distributed in both the
nucleus and the cytoplasm, similar to that detected by
the luciferase probe. However, the released S1R1 aptamer
was not detectable by the S1R1 probe (Figure 4D mid-
dle panel), suggesting that the S1R1 aptamer released by
Dicer processing was rapidly degraded, similar to the ter-
minal loops and the passenger strand of miRNAs. These
results showed that aptamers incorporated into the termi-
nal loop of an shRNA could be exported to the cytoplasm
and the shRNA–aptamer fusion could be maintained at a
high steady state level. In contrast, the released aptamer did
not accumulate to detectable levels.
shRNA–aptamer fusions inhibit lentivirus replication
Despite an undetectable steady state level of released ap-
tamer from the shRNA–aptamer fusion, the high level of
shLuc-aptamer fusion may still bind to and inhibit inte-
grase function. To test this possibility, we first tested if the
stem of the shRNA affected the binding affinity of the ap-
tamer using a gel mobility assay (Figure 5A). The binding
affinity of S1R1 to HIS-IN was 101 nM ± 20 while that of
shLuc-S1R1 was not clearly distinguishable at 121 nM ±
32 (P = 0.8536) (Figure 5B), suggesting that the addition
of the shLuc stem did not appreciably alter the binding of
the aptamer S1R1 to integrase. We next tested if the shLuc-
S1R1 and other fusions contained any anti-HIV activity
in a functional assay. Stable HEK293 cell lines express-
ing the shLuc alone, fusions of shLuc-S1R1, shLuc-S3R1
and shLuc–S3R3 were generated. When infected by lentivi-
ral particle HIV-7-GFP, all three shLuc-aptamers fusions
showed moderate but consistent inhibition of GFP expres-
sion, ranging from 20% to 30% (Figure 5C andD). This was
an improvement compared to aptamer alone driven by the
same U6 promoter (Supplementary Figure S3A and 3B).
These results indicated that when expressed from U6 pro-
moter, the shRNA–aptamer fusions have higher anti-HIV
activity than the aptamers alone.
To test if the shRNA-fusions can exert inhibition during
subsequent infection cycles, we repeated our assays using
replication competentHIV.We generated stable cell lines ex-
pressing the shLuc alone and the shLuc-S1R1, shLuc-S3R1
and shLuc–S3R3 fusions inGhost3 +CXCR4+CCR5 cells
(abbreviated as Ghost3 cells in following text) (27). We then
infected the Ghost3 lines with the M-tropic HIV-1 Ba-L
strain at a MOI of 0.02. The viral concentration in cultures
was monitored by p24 assay for 9 days. While shLuc-S1R1
and shLuc-S3R1 showed similar inhibition level as single
cycle infection at 20–30% inhibition, shLuc–S3R3 consis-
tently showed 85% inhibition towards replication compe-
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e6 Nucleic Acids Research, 2018, Vol. 46, No. 1 PAGE 10 OF 15
tent HIV viruses (Figure 6A and B) suggesting that the
shRNA–aptamer fusions could be more effective in multi-
ple infection cycles.
To further test if this strategy could be applied to ap-
tamers targeting proteins primarily function in the cyto-
plasm, a fusion of shLuc and an RT aptamer (shLuc-70.15)
was constructed (41). Stable Ghost3 cells expressing shLuc,
70.15 or shLuc-70.15 fusion were challenged by Ba-L strain
HIV and the p24 concentration in cultures were monitored
for 9 days. Like the results found in IN aptamers, expressed
shLuc-70.15 fusion showed stronger HIV inhibition than
the RT aptamer alone (Figure 6C and D), suggesting that
fusing an shRNA to an aptamer could enhance its efficacy
and that this strategy could be used to target cytoplasmic
proteins.
Aptamer S3R3 in combination with an shRNA targeting Tat-
Rev has similar potency as the integrase inhibitor Raltegravir
We used the same assay to further test the efficacy of three
other candidates S3R4, S3R6 and S4R2. S3R3 remained the
most effective in inhibiting proliferation ofHIV-1 inGhost3
cells, consistently showing 80–85% p24 reduction compare
to the control cells expressing shLuc (Supplementary Fig-
ure S4A and 4B). Moreover, S3R3 showed a higher affinity
(47nM± 3) towardHIS-IN than S1R1 (101 nM± 20) (Sup-
plementary Figure S5A and 5B). Therefore, we focused on
S3R3 for further studies.
First, we compared the anti-HIV activities of S3R3 to
that of an shRNA directed against the HIV Tat-Rev region
(shS1) (42). Stable Ghost3 cells expressing shS1 were gen-
erated. These cells were then infected with the HIV Ba-L
strain at a MOI of 0.02 for 9 days. p24 levels were com-
pared to those from cells expressing the shLuc control and
shLuc–S3R3. We found that shS1 cells showed two-fold
stronger inhibition than shLuc–S3R3 at day 6.However, the
difference became less at day 9 when shLuc–S3R3 showed
78% inhibition while shS1 showed 88% inhibition (Figure
7A and B). To test if shS1 and S3R3 exhibited synergy in
inhibiting HIV propagation, a similar plasmid expressing
a fusion RNA of shS1 and S3R3 (shS1–S3R3) was con-
structed. Stable Ghost3 cells lines were generated and then
challenged with HIV-1 Ba-L strain. Although each individ-
ual RNA provided 80–90% inhibition of HIV replication,
the combined shS1–S3R3 fusion RNA resulted in a 100-
fold stronger inhibition than the single RNA at day 9 (Fig-
ure 7A and B).
To further assess the potency of the aptamer S3R3, we
compared the efficacy of shLuc–S3R3 and the shS1–S3R3
to the FDA approved anti-integrase drug Raltegravir. We
monitored HIV Ba-L proliferation in Ghost3 cells express-
ing shLuc–S3R3 to that of control cells expressing shLuc
in the presence or absence of Raltegravir. We tested 2nM
and 20nM concentration of Raltegravir, corresponding to
IC50 and IC95 in 10% FBS cell culture (43,44). As ob-
served previously, shLuc–S3R3 showed 80–85% inhibition
at day 9 compared to 96% inhibition for 2nM and >99%
inhibition for 20 nM Raltegravir (Figure 7C and D). These
results showed that S3R3 alone possessed anti-HIV activ-
ity that was weaker than a low dose of Raltegravir. On
the other hand, the combination of shS1 and S3R3 (shS1–
S3R3) showed much stronger inhibition with a p24 level
comparable to those treated with a high dose of Raltegravir
(Figure 7C and D). These results demonstrated that com-
bining anti-HIV shRNA and anti-integrase aptamers could
be a very effective gene therapy strategy against HIV.
Aptamer S3R3 is effective in long-term inhibition of HIV
replication
We further tested the long-term efficacy of shRNA–
aptamer fusions in CD4 positive T cell line. Stable CEM cell
lines expressing shLuc, shLuc–S3R3, shS1 or shS1–S3R3
were generated (see Material and Method). 1 × 105 stable
cells were then infectedwith T-tropicHIVpNL4-3 at aMOI
of 0.01. Viral concentrations were monitored for 6 weeks by
p24 assay (Figure 8). Surprisingly, aptamer alone (shLuc–
S3R3) and shRNA alone (shS1) showed similar efficacy as
the combination (shS1–S3R3). In all cases, the viral concen-
tration was more than three orders of magnitude lower than
that of control (shLuc) and did not increase over the ob-
served 6 weeks. This inhibition was much stronger than that
observed in Ghost3 cells (compare Figure 8 to Figure 7).
Aptamer S3R3 was selected against integrase derived from
pNL4-3 strain. This might explain a much stronger inhibi-
tion in this assay than in the short-term assays that chal-
lenged by the Ba-L strain. Alternatively, the fusions might
exhibit higher potency in its natural host of T cells than in
the engineered Ghost3 cell. In summary, anti-integrase ap-
tamer expressed as an shRNA–aptamer fusion can confer
long term resistance to HIV-1 replication in T cells. This
strategy of expressing an aptamer into the terminal loop of
an shRNA can be applicable for gene therapy against HIV
and can potentially be adopted to treat other diseases.
DISCUSSION
In this study, we developed a strategy to select and stably
express RNA aptamers against the HIV integrase and re-
verse transcriptase. By incorporating the aptamers into the
terminal loop of an shRNA, we achieved long-term inhi-
bition of HIV replication in a cell culture system. The SE-
LEX method has been useful for isolating RNA aptamers
against specific protein targets. Typically, aptamers with
high binding affinity are selected by binding to a single solu-
ble protein. Applying this approach to unstable or low sol-
ubility proteins such as the HIV integrase has been tech-
nically challenging. Tags such as MBP, HIS and FLAG
can improve solubility and/or stability of the tagged pro-
teins and thus facilitate purification and selection. Varying
the capture method is a longstanding approach to reduce
background. We employed multiple tagged proteins in al-
ternate selection cycles in a modified SELEX protocol, we
termed multi-tag SELEX. This method allows the selection
of aptamers against low solubility or unstable proteins while
minimize non-specific binding to the tags. In most cases,
target proteins expressed in mammalian cells is preferable
over bacterially expressed ones. HIV integrase undergoes
various post-translational modifications such as phospho-
rylation, acetylation and sumoylation in mammalian cells
(45). This increase the likelihood of obtaining functional ap-
tamers against modified IN protein. Furthermore, the inte-
grase should be in its native conformation and therefore, be
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Figure 6. Expressed shRNA–aptamer fusions exhibited stronger inhibition of HIV replication in multiple cycle infection. (A) shLuc integrase aptamer
fusions (shLuc-S1R1, shLuc-S3R1, shLuc–S3R3) inhibited Ba-L strain virus replication in Ghost3 cells to different extents. (B) Inhibition of HIV repli-
cation at day 9 post-infection. C. Expressed shLuc RT aptamer fusion (shLuc-70.15) exhibited stronger inhibition than expressed RT aptamer (70.15)
alone.D. Inhibition of HIV replication at day 9 post-infection. In A and C, single representative experiment with triplicate samples are shown. In B and D,
percentage inhibition is represented by relative p24 concentration to shLuc control. Averages and standard deviations of two (D) or three (B) independent
biological assays are shown.
more likely to form complexes with other cellular proteins
(31–34). This increases the chance of obtaining aptamers
against IN protein epitopes available in host cells. Ideally,
selection should be alternated among all three tagged pro-
teins. However, the limited yield of FLAG-IN restricted the
use of FLAG-tagged integrase to only one selection cycle.
Nevertheless, using this strategy, we have successfully iso-
lated the first RNA aptamers that target HIV integrase un-
der physiological salt concentrations. This strategy should
see general applications for other difficult and specific tar-
gets, such as a functional domain of a protein that may have
low solubility. Importantly, his method also allows selection
of more physiologically relevant aptamers.
Another hurdle for using aptamers in gene therapy is the
lack of sustained expression. Currently, most nucleic acid
aptamers are administered extracellularly to block interac-
tion of surface receptor and viral proteins. Some aptamers
can be internalized together with the receptors. However,
this method only allows a limited level of delivery and is
subject to cyclical variation. A sustained high level of RNA
aptamer can be achieved by Pol III promoter driven ex-
pression. However, without an intrinsic nuclear export sig-
nal, Pol III transcripts stay in the nucleus, thereby limiting
their application for targeting nuclear proteins, such as tran-
scription factors (18,20,21,46–48). By incorporating the ap-
tamer into the terminal loop of an shRNA, the U6 pro-
moter driven shRNA–aptamer fusions persisted at a high
level in the nucleus and the cytoplasm. A portion of the fu-
sion is processed by Dicer, resulting in knockdown of target
genes. We could not detect the released aptamer moiety in a
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Figure 7. shS1–S3R3 fusion has comparable efficacy as Integrase inhibitor Raltegravir. (A and B) shS1 and aptamer S3R3 (shS1–S3R3) showed synergistic
inhibition against Ba-L HIV replication in Ghost3 cells. (A) Changes in virus concentration in Ghost3 cells infected with Ba-L virus were monitored by
p24 assays. (B) Percentage inhibition represented by relative p24 concentration to shLuc control is shown at day 6 and day 9 post-infection. (C and D)
shS1–S3R3 showed efficacy comparable to integrase inhibitor Raltegravir. (C) Changed in virus concentration in Ghost3 cells infected with Ba-L virus. (D)
Inhibition of HIV replication at day 9 post-infection. In A and C, single representative experiment with triplicate samples are shown. Y-axis uses semi-log
scale so only positive errors are shown. In B and D, averages and standard deviations of two independent assays are shown.
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Figure 8. shRNA–aptamer fusions confer long-term resistance to HIV replication in T cells. (A) Changes in virus concentration in CEM cells infected
with pNL4-3 virus were monitored by p24 assays for 6 weeks. (B) p24 concentration at the end of week 6 post infection. In panel A, a single representative
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of two independent assays are shown.
Northern blot assay, consistent with the rapid degradation
of uncapped and unprotected RNA in the cytoplasm. How-
ever, the shRNA–aptamer fusions targeting either IN or RT
exhibited a stronger inhibition than the aptamer alone. The
mechanism of this enhancement is not clear. In principle,
several factors or a combination of them could contribute
to a stronger inhibition. The shRNAs facilitated the export
of the fusions to the cytoplasm where newly translated viral
polyproteins might bemore susceptible to aptamer binding.
The stronger inhibition observed in multiple infection cycle
than in single infection cycle suggested that this might be
one of the mechanism. The stem structure of an shRNA
is very stable. It could have stabilized the active aptamer
structures and/or increased the steady-state levels of the pri-
mary transcript. Importantly, the integrase aptamer S3R3
showed a strong synergy with an shRNA targeting the tat-
rev region and together the shS1–S3R3 fusion exhibited a
very strong and prolonged inhibition of HIV replication in
cell cultures.
This strategy of combining shRNAs and aptamers al-
lows both sequence-based and structure-based targeting
by one shRNA–aptamer fusion. The shRNA and aptamer
combination allows flexibility in targeting either the same
gene (protein and mRNA), two genes (one protein and one
mRNA) or one protein plus one non-coding RNA. More-
over, by using multiplexed vectors (7), multiple shRNA–
aptamer fusions can be expressed from a single transcript.
This allows inhibition of multiple targets at once and will
be particularly useful to combat the ever-evolving HIV.
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